Drug intelligence / Profile preview

MK-1084 + cetuximab

Development stage: Unknown
Lead developer: Merck
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Oral, Intravenous

Overview

MK-1084 + cetuximab is an investigational combination therapy for KRAS G12C-mutant metastatic colorectal cancer. MK-1084 is a next-generation selective covalent inhibitor of KRAS G12C, a mutation found in various solid tumors, notably colorectal and non-small cell lung cancer. Cetuximab is a chimeric monoclonal antibody targeting the epidermal growth factor receptor (EGFR), widely used in colorectal cancer. In the KANDLELIT-001 Phase 1 trial, this combination demonstrated antitumor activity and a manageable safety profile in patients with advanced previously treated colorectal cancer. MK-1084 is orally administered, while cetuximab is given intravenously. The combination is undergoing further clinical trials, including a Phase 3 trial in first-line advanced colorectal cancer.[1][3]

Brand names: Erbitux
Other names: cetuximab

Targets

EGFR T790M (Epidermal growth factor receptor T790M mutant)KRASG12C (Kirsten rat sarcoma viral oncogene homolog G12C)

Beyond the preview

Go deeper on MK-1084 + cetuximab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MK-1084 + cetuximab.

Explore the full profile